Sulindac. Trials of a new anti-inflammatory drug.
Trials in patients with rheumatoid arthritis and osteoarthritis showed sulindac to be an analgesic with anti-inflammatory properties and at least as effective as aspirin. It was effective within 24 hours in doses of 300-400 mg daily. It had the advantages of twice daily administration and a lower incidence of gastric side effects than aspirin. Constipation, usually mild, occurred in 20-30% of cases. Like other anti-inflammatory drugs, it was effective in only a proportion of the patients.
D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001241:Aspirin / Q000627:therapeutic use; D001597:Benzylidene Compounds / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D007192:Indenes / Q000009:adverse effects / Q000627:therapeutic use*; D010003:Osteoarthritis / Q000188:drug therapy*
D001597:Benzylidene Compounds; D007192:Indenes; D001241:Aspirin